INTRODUCTION: Considerable attention has been given to the screening and optimization of treatment of @entity1 with type 2- @entity6 in the period 2000-2005. The aim of this paper is to evaluate the prevalence of @entity1 with type 2- @entity6 and the quality of @entity6 care provided in the period 2000 to 2005. MATERIAL AND METHODS: Using a previously evaluated method, all @entity1 with type 2- @entity6 were identified and described on the basis of register data in what was then the County of Aarhus. RESULTS: A total of 11,436 @entity1 with type 2- @entity6 were identified in the age group 40-70 years, corresponding to a prevalence of 4.61%. In 2005 58% were in antidiabetic pharmacological treatment, 68% of whom received oral antidiabetic treatment, 15% were on insulin alone and 16% received a combination treatment including insulin and oral treatment. Furthermore, a total of 50% of the included @entity1 were on lipid-lowering treatment of whom 99% were in statin-therapy. One or more measurements of HbA1c were taken in 87% of the @entity1 in 2001 compared with 81% in 2005 (p < 0.000). A total of 60% had an @entity4051 c < 8 in 2001 compared with 67% in 2005 (p < 0.000). In 2001 72% had a @entity165 measurement compared with 77% in 2005 (p < 0.000). A total of 23% had a @entity165 value < 4.5. mmol/l in 2001 compared with 42% in 2005 (p < 0.000). CONCLUSION: During a period of five years the prevalence of @entity1 with type 2- @entity6 increased. In the same period, improvement was seen in the quality indicators of HbA1c and @entity165 level. There is, however, still room for improvement.

[Quality indicators of type 2- XXXX monitoring during 2000-2005].

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity4051 :: ('3039', 'Gene') :: ['HbA1']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes']
